SYRINX has extensive experience of developing new methods using state-of-the-art immunological and cell based techniques for pharmacokinetic (PK) sample analysis.
Our laboratory employs various plate and cellbased technologies, such as TR-FIA, ECL, AlphaLISA, iLITE, TR-FRET, RIA, SPR and ELISA, to assess the immunogenicity of biological drugs and vaccines.
Patient monitoring services are now available!
Concentration/activity analysis and immunogenicity testing using the iLite™ technology platform.
SYRINX is a Contract Research Organization (CRO) offering a large variety of modern immunoassay techniques for the bioanalysis of Biologicals, Biosimilars, Anti-drug antibodies (immunogenicity testing) and Biomarkers.
SYRINX performs bioanalytical studies in compliance with GLP/GCP and also supports GMP analysis for batch release and stability studies. We are continuously striving to fulfill the latest guideline and white paper requirements.
SYRINX Bioanalytics is included in the OECD principles of good laboratory practice (GLP) and EU good manufacturing practice (GMP analytics) monitoring programs.
SYRINX Bioanalytics offers a wide range of state-of-the-art assay techniques ideal for the bioanalysis of biologicals/biosimilars, anti-drug antibodies, vaccines and biomarkers.
CROFinland - Taste of Excellence
A Combination of four Finnish CROs, providing services in Clinical, Statistical & Data Management, Bioanalytical, Pharmacovigilance and Regulatory.
SYRINX will attend the "NLS (Nordic Life Science) days 2018" 10-12 September 2018 in Stockholm, Sweden.
SYRINX will attend the "EBF - Focus Workshop: Today’s challenges and solutions in assessing immunogenicity in patients" 19-20 September 2018 in Lisbon, Portugal.
SYRINX attended the "EBF Focus Workshop - New Modalities and Novel Concepts in Bioanalysis" 14-16 May 2018 in Lisbon, Portugal.
SYRINX is a member of the European Bioanalysis Forum (EBF) together with more than 50 other Pharma and CRO companies.
SYRINX interview is available at Gyros webpage: "In the future, CROs will be in constant communication with their customers and truly become part of the team developing new biologicals".